JP2015511957A5 - - Google Patents

Download PDF

Info

Publication number
JP2015511957A5
JP2015511957A5 JP2014560367A JP2014560367A JP2015511957A5 JP 2015511957 A5 JP2015511957 A5 JP 2015511957A5 JP 2014560367 A JP2014560367 A JP 2014560367A JP 2014560367 A JP2014560367 A JP 2014560367A JP 2015511957 A5 JP2015511957 A5 JP 2015511957A5
Authority
JP
Japan
Prior art keywords
salt
ethoxy
arginine
phosphonoethoxy
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014560367A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511957A (ja
JP6325986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/054548 external-priority patent/WO2013131985A1/en
Publication of JP2015511957A publication Critical patent/JP2015511957A/ja
Publication of JP2015511957A5 publication Critical patent/JP2015511957A5/ja
Application granted granted Critical
Publication of JP6325986B2 publication Critical patent/JP6325986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014560367A 2012-03-07 2013-03-07 免疫学的に有用なアルギニン塩 Active JP6325986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
US61/608,011 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (3)

Publication Number Publication Date
JP2015511957A JP2015511957A (ja) 2015-04-23
JP2015511957A5 true JP2015511957A5 (enExample) 2016-04-28
JP6325986B2 JP6325986B2 (ja) 2018-05-16

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014560367A Active JP6325986B2 (ja) 2012-03-07 2013-03-07 免疫学的に有用なアルギニン塩

Country Status (18)

Country Link
US (1) US9320748B2 (enExample)
EP (1) EP2822947B1 (enExample)
JP (1) JP6325986B2 (enExample)
CN (1) CN104203946B (enExample)
AU (1) AU2013229466A1 (enExample)
CA (1) CA2865759C (enExample)
CY (1) CY1118091T1 (enExample)
DK (1) DK2822947T3 (enExample)
ES (1) ES2597755T3 (enExample)
HR (1) HRP20161354T1 (enExample)
HU (1) HUE030175T2 (enExample)
LT (1) LT2822947T (enExample)
MX (1) MX346678B (enExample)
PL (1) PL2822947T3 (enExample)
PT (1) PT2822947T (enExample)
RU (1) RU2014140336A (enExample)
SI (1) SI2822947T1 (enExample)
WO (1) WO2013131985A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US9375471B2 (en) 2012-03-08 2016-06-28 Glaxosmithkline Biologicals Sa Adjuvanted formulations of booster vaccines
EP3122378B1 (en) 2014-03-26 2019-12-11 GlaxoSmithKline Biologicals S.A. Mutant staphylococcal antigens
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
EP4114463A4 (en) * 2020-03-01 2023-09-06 Dynavax Technologies Corporation CORONAVIRUS VACCINES INCLUDING A TLR9 AGONIST
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
WO1993018150A1 (en) 1992-03-02 1993-09-16 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
JPH10502365A (ja) 1994-07-01 1998-03-03 リカン・リミテッド ヘリコバクタータンパク質およびワクチン
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
JP4896715B2 (ja) 2003-06-26 2012-03-14 ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド Chlamydiatrachomatisに対する免疫原性組成物
RU2006134631A (ru) 2004-03-02 2008-04-10 Чирон Корпорейшн (Us) Иммуногенные композиции против chlamidia pneumoniae
ES2595363T3 (es) 2005-02-18 2016-12-29 J. Craig Venter Institute, Inc. Sepsis asociada a las proteínas y los ácidos nucleicos de meningitis / Escherichia coli
US8062644B2 (en) 2005-02-18 2011-11-22 Novartis Vaccines & Diagnostics Srl. Immunogens from uropathogenic Escherichia coli
EP1891096A2 (en) 2005-05-12 2008-02-27 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
EP1976557A2 (en) 2005-12-22 2008-10-08 Novartis Vaccines and Diagnostics S.r.l. Chlamydial antigens
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
NZ584683A (en) 2007-10-19 2012-05-25 Novartis Ag Neisseria meningitidis serogroup B vaccine formulations
CA2758490C (en) 2009-04-14 2023-05-02 Novartis Ag Compositions for immunising against staphylococcus aureus
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
CN102762226A (zh) * 2009-06-10 2012-10-31 诺华有限公司 含苯并萘啶的疫苗
BR112012004275A2 (pt) 2009-08-27 2016-11-16 Novartis Ag polipeptídios híbridos incluindo sequências meningocócicas de fhbp
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
CN105999275A (zh) 2010-09-01 2016-10-12 诺华有限公司 免疫增强剂吸附不溶性金属离子
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
KR20140066212A (ko) * 2011-09-01 2014-05-30 노파르티스 아게 스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물

Similar Documents

Publication Publication Date Title
JP2015511957A5 (enExample)
JP2013534248A5 (enExample)
CN112469713A (zh) 芳基磷氧化物类衍生物抑制剂、其制备方法和应用
RU2014140336A (ru) Иммунологически полезные соли аргинина
JP2013515742A5 (enExample)
JP2014525429A5 (enExample)
JP2018531941A5 (enExample)
JP2008542286A5 (enExample)
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
HRP20170433T1 (hr) Pripravci spoja za izmjenu lipidiranog imunološkog odgovora, formulacije, i postupci
WO2015017821A3 (en) Therapeutically active compounds and their methods of use
JP2014500861A5 (enExample)
JP2014507446A5 (enExample)
GEP201706780B (en) Substituted 2-aza-bicyclo [2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2016531894A5 (enExample)
JP2014513123A5 (enExample)
JP2016516074A5 (enExample)
JP2013519645A5 (enExample)
JP2014218522A5 (enExample)
JP2016534081A5 (ja) ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法
JP2012513416A5 (enExample)
JP2015522037A5 (enExample)
JP2011046708A5 (enExample)
JP2015516419A5 (enExample)